Mupirocin ointment for dogs

Mupirocin ointment for dogs

Mupirocin ointment for dogs treats canine bacterial skin infections, including superficial pyoderma, caused by susceptible strains of Staphylococcus aureus and Staphylococcus intermedius.

Dosage and Administration

Cleanse the lesion before treatment. Apply Mupirocin Ointment USP, 2% to the affected area twice daily. Use enough ointment to fully cover the affected area. Limit the treatment duration to a maximum of 30 days.

Contraindications

Do not use Mupirocin ointment in animals with a known sensitivity to any of its components.

Warnings and Precautions

Do not use Mupirocin ointment for ophthalmic purposes.

Pregnancy and Lactation

The safety of this product in pregnant or breeding animals has not been established.

Adverse Drug Reactions

No adverse reactions have been reported. Discontinue treatment and provide appropriate care if a skin reaction, such as irritation, occurs.

Overdosage

An overdose of antibiotic ointment for dogs is unlikely. If an overdose is suspected, seek emergency veterinary treatment immediately.

Clinical Pharmacology: Mupirocin is a chemical entity produced by fermentation of the organism Pseudomonas fluorescens. Mupirocin inhibits bacterial protein synthesis by reversibly and specifically binding to bacterial isoleucyl transfer-RNA synthetase. Due to this mode of action, mupirocin shows no cross resistance with chloramphenicol, erythromycin, gentamicin, lincomycin, neomycin, novobiocin, penicillin, streptomycin and tetracycline.

Mupirocin is an antimicrobial agent that inhibits the growth of gram-positive and gram-negative bacteria. Bacteria susceptible to the action of mupirocin in vitro include the aerobic isolates of Staphylococcus aureus (including methicillin-resistant strains and β-lactamase-producing strains), Staphylococcus intermedius, Staphylococcus epidermidis, other coagulase positive or negative Staphylococci, α-hemolytic Streptococci, β group A Streptococci (including S. pyogenes), other β Streptococci (including S. agalactiae), group D Streptococci (including S. faecalis and S. faecium), group Viridans Streptococci, Streptococcus pneumoniae, Corynebacterium hofmanii, Bacillus subtilis, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Proteus vulgaris, Enterobacter cloacae, Enterobacter aerogenes, Citrobacter freundii, Hemophilus influenzae (including β-lactamase-producing strains), Neisseria gonorrheae (including β-lactamase-producing strains), Neisseria meningitidis, Branhamella catarrhalis and Pasteurella multocida, and the anaerobic isolates of Peptostreptococcus anaerobius, Clostridium difficile and Clostridium sporogenes.